Merck’s Immune System-Based Cancer Drug Works in 1 in 4 – Bloomberg

by lowes1 on October 7, 2013

Merck's Immune System-Based Cancer Drug Works in 1 in 4
Bloomberg
In a trial of 38 patients with non-small cell lung cancer, 24 percent had an immune-system response to the drug, called MK-3475 and previously known as lambrolizumab, Merck said today in a statement. Using a measure of whether their tumors shrank, 

and more »

View full post on lung cancer – Google News

Leave a Comment

Previous post:

Next post: